GW Pharma’s Epidiolex Achieves Statistical Significance in Third Phase 3 Trial for Treatment of Rare Pediatric Epilepsy

Print More

GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome – Primary endpoint achieved in both Epidiolex doses with high statistical significance ...read more

Comments are closed.